Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

Autor:	Lucia Tornaghi, Carlo Gambacorti-Passerini, Anna Franceschino, Sarit Assouline, Valerie Benemacher
Přispěvatelé:	Franceschino, A, Tornaghi, L, Benemacher, V, Assouline, S, GAMBACORTI PASSERINI, C
Jazyk:	angličtina
Rok vydání:	2008
Předmět:	Adult Male medicine.medical_specialty medicine.drug_class Antineoplastic Agents Creatine Piperazines Tyrosine-kinase inhibitor Phosphates chemistry.chemical_compound Metabolic Diseases Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine imatinib cml ck phophate lipid medicine Humans Creatine Kinase Aged Retrospective Studies biology business.industry Myeloid leukemia Imatinib Hematology Middle Aged Lipid Metabolism medicine.disease Leukemia Pyrimidines Endocrinology Imatinib mesylate chemistry Benzamides Imatinib Mesylate biology.protein Female Creatine kinase business medicine.drug Chronic myelogenous leukemia
Popis:	Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7619ca065d2f85a81afd48ddacfec79 http://hdl.handle.net/10281/552 Zobrazit plný text záznamu